| abstract |
The present invention describes 4,6-diphenyl-1H-pyrazolo[3,4-Jb]pyridin-3-amine (EB1), or a pharmaceutically acceptable salt thereof, as a selective MNK inhibitor for use in the treatment of cancers of an hormone-dependent organs, -including triple-negative breast cancer, prostate cancer and other referable cancers with p-elF4E overexpression due to increased MNK activity. The invention also includes particular therapeutic combinations including the 4,6-diphenyl-1H-pyrazolo[3,4-Jb]pyridin-3-amine. |